Heptromic. Genomic predictors and oncogenic drivers in hepatocellurlar carcinoma

  • Heptromic Genomic predictors and oncogenic drivers in hepatocellular carcinoma. Watch the video
  • Heptromic will optimise decision-making for liver cancer patients by identifying genomic prognostic determinants and oncogenic drivers.
  • Heptromic’s core team comprises leading European researchers in the basic, translational and clinical fields of liver cancer.
  • Heptromic is a 3-year translational research project which aims to solve core problems in the management of hepatocellular carcinoma (HCC), the third most common cause of cancer-related death worldwide.


  • IDIBAPS participates in a 5.7M European project to improve knowledge on liver cancer

    The Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in a European project to identify the molecular mechanisms that have a direct impact on the development of hepatocellular carcinoma (HCC). The HEP-CAR project will evaluate the role of these mechanisms in different liver diseases leading to HCC -the infection by hepatitis B and C, overweight or alcohol-. This research initiative, coordinated by the University of Freiburg and in which ten European academic centers are involved, is part of Horizon 2020, the European Comission framework programme for research and innovation, and it is endowed with a budget of 5.7 million euros, one of them corresponding to IDIBAPS.

    September 2015

  • A pioneering study correlates genetic alterations and environmental factors in liver cancer

    IDIBAPS researchers have participated in a pioneering study in hepatocellular carcinoma, the most common liver cancer, in which all the genetic alterations that occur in this type of tumor have been characterized. In an article published in the journal Nature Genetics scientists provide a complete overview of the disease and these genetic alterations associated with the etiology and clinical characteristics, the proposed treatments for patients approved for other cancers, which could be applied in each case. Dr. Josep Maria Llovet, ICREA professor at the IDIBAPS Hepatic Oncology Group and director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York), and Dr. Roser Pinyol, researcher at the same group, have participated in this article led by Dr. Jessica Zucman-Rossi, from the INSERM-Paris. 

    March 2015

More news



More events


Scientific Publications

More scientific publications

Heptromic Partners

Fondazione IRCCS Istituto Nazionale dei tumori (INT)

Prof. Vincenzo Mazzaferro

Fondazione IRCCS Istituto Nazionale dei tumori (INT)

Prof. Vincenzo Mazzaferro

Clinical expertise

Project led by: Idibaps

Copyright © 2010 - 2015 HEPTROMIC

HEPTROMIC is a project in the 'Health' Theme of the Specific Programme 'Cooperation' of the European Commission's Seventh Framework Programme.